Apr 18 |
PainReform Announces Closing of $4 Million Public Offering
|
Apr 16 |
PainReform prices its $4M offering at $0.80 apiece; shares fall
|
Apr 16 |
PainReform Announces Pricing of $4 Million Public Offering
|
Apr 9 |
PainReform’s Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions
|
Apr 9 |
EXCLUSIVE: PainReform's Non-Opiate Post-Surgical Pain Relief Treatment Outperforms Rival Medicine Under Various Testing Conditions
|
Apr 2 |
EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug
|
Apr 2 |
PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy
|
Mar 1 |
PainReform files to sell shares
|
Mar 1 |
PainReform Provides Year-End Business Update
|
Jan 22 |
PainReform to Present at the Microcap Conference in Atlantic City
|